info@seagull-health.com

SeagullHealth

语言:

Homepage

Drugs

Adagrasib(Krazati)

Names

Krazati,Adagrasib,MRTX849,阿达格拉西布

Indicatons

Locally advanced or metastatic NSCLC harboring KRAS G12C mutation who have received at least one systemic therapy.

Price:

Manufacturer:

Mirati

Dosage form:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Krazati(Adagrasib) Instructions:Uses,Dosage, Side Effects

Adagrasib, branded as KRAZATI, is an oral medication that targets KRAS G12C mutations, offering a targeted therapy option for patients with KRAS G12C-mutated non-small cell lung cancer and colorectal cancer. The drug works by irreversibly inhibiting the mutated KRAS protein, blocking its abnormal signaling pathway, and inhibiting tumor growth.

It is used both as a single agent for NSCLC and in combination with cetuximab for the treatment of CRC. It has shown promising results in clinical trials, providing a treatment option for patients with limited alternatives due to previous systemic therapies.

Generic name

Adagrasib(Krazati)

English name

Adagrasib

Alternative Names

Krazati,Adagrasib,MRTX849,阿达格拉西布

Drug prices

Indications

KRAZATI (adagrasib) is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) that harbor the KRAS G12C mutation. This includes patients who have received at least one prior systemic therapy.

Therapeutic Target

KRAS G12C

Active Ingredients

Adagrasib

Dosage Form

TABLET

Specifications

200mg*180 capsules

Dosage and Administration

The recommended dose of KRAZATI is 600 mg orally once daily.

Related Columns

Recommended articles

Precautions for Adagrasib Administration

Adagrasib is an irreversible inhibitor of KRASG12C, primarily indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) with KRASG12C...

Side Effects of Adagrasib

Adagrasib is an irreversible inhibitor of KRASG12C mutation, indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) with KRASG12C ...

Dosage and Administration of Adagrasib

Adagrasib is an irreversible inhibitor of KRASG12C mutation, mainly used for the treatment of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) with specific gene mutations.Dosage and Adm...

What Are the Indications of Adagrasib?

Adagrasib is an innovative KRASG12C inhibitor, which was first approved for marketing in the United States in 2022. As a major breakthrough in the field of targeted therapy, this medication provides a...

What Are the Purchase Channels for Adagrasib?

Adagrasib is an innovative KRASG12C-targeted inhibitor that has shown promising efficacy in the treatment of non-small cell lung cancer and colorectal cancer.What Are the Purchase Channels for Adagras...

Precautions for use of Adagrasib

Adagrasib is an important therapeutic drug, and its correct use and precautions are crucial to ensure the therapeutic effect.Precautions for use of AdagrasibUnderstanding and following the precau...

Departments